Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report

Lung cancer is the leading cause of mortality among malignant diseases in humans worldwide. During the last decade, molecular targeted therapies for non-small cell lung cancer using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefi...

Descripción completa

Detalles Bibliográficos
Autores principales: WANG, YUE FENG, XIANG, XIANHONG, PEI, XIAOJUAN, LI, SHUHUA, TANG, CUILAN, WANG, LIANTANG, KE, ZUN-FU
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114585/
https://www.ncbi.nlm.nih.gov/pubmed/25120654
http://dx.doi.org/10.3892/ol.2014.2321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114585/
https://www.ncbi.nlm.nih.gov/pubmed/25120654
http://dx.doi.org/10.3892/ol.2014.2321

Ejemplares similares